Back to Search Start Over

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

Authors :
Vieira-Silva, Sara
Falony, Gwen
Belda, Eugeni
Nielsen, Trine
Aron-Wisnewsky, Judith
Chakaroun, Rima
Forslund, Sofia K
Assmann, Karen
Valles-Colomer, Mireia
Nguyen, Thi Thuy Duyen
Proost, Sebastian
Prifti, Edi
Tremaroli, Valentina
Pons, Nicolas
Le Chatelier, Emmanuelle
Andreelli, Fabrizio
Bastard, Jean-Phillippe
Coelho, Luis Pedro
Galleron, Nathalie
Hansen, Tue H
Hulot, Jean-Sébastien
Lewinter, Christian
Pedersen, Helle K
Quinquis, Benoit
Rouault, Christine
Roume, Hugo
Salem, Joe-Elie
Søndertoft, Nadja B
Touch, Sothea
Dumas, Marc-Emmanuel
Ehrlich, Stanislav Dusko
Galan, Pilar
Gøtze, Jens P
Hansen, Torben
Holst, Jens J
Køber, Lars
Letunic, Ivica
Nielsen, Jens
Oppert, Jean-Michel
Stumvoll, Michael
Vestergaard, Henrik
Zucker, Jean-Daniel
Bork, Peer
Pedersen, Oluf
Bäckhed, Fredrik
Clément, Karine
Raes, Jeroen
Vieira-Silva, Sara
Falony, Gwen
Belda, Eugeni
Nielsen, Trine
Aron-Wisnewsky, Judith
Chakaroun, Rima
Forslund, Sofia K
Assmann, Karen
Valles-Colomer, Mireia
Nguyen, Thi Thuy Duyen
Proost, Sebastian
Prifti, Edi
Tremaroli, Valentina
Pons, Nicolas
Le Chatelier, Emmanuelle
Andreelli, Fabrizio
Bastard, Jean-Phillippe
Coelho, Luis Pedro
Galleron, Nathalie
Hansen, Tue H
Hulot, Jean-Sébastien
Lewinter, Christian
Pedersen, Helle K
Quinquis, Benoit
Rouault, Christine
Roume, Hugo
Salem, Joe-Elie
Søndertoft, Nadja B
Touch, Sothea
Dumas, Marc-Emmanuel
Ehrlich, Stanislav Dusko
Galan, Pilar
Gøtze, Jens P
Hansen, Torben
Holst, Jens J
Køber, Lars
Letunic, Ivica
Nielsen, Jens
Oppert, Jean-Michel
Stumvoll, Michael
Vestergaard, Henrik
Zucker, Jean-Daniel
Bork, Peer
Pedersen, Oluf
Bäckhed, Fredrik
Clément, Karine
Raes, Jeroen
Source :
Vieira-Silva , S , Falony , G , Belda , E , Nielsen , T , Aron-Wisnewsky , J , Chakaroun , R , Forslund , S K , Assmann , K , Valles-Colomer , M , Nguyen , T T D , Proost , S , Prifti , E , Tremaroli , V , Pons , N , Le Chatelier , E , Andreelli , F , Bastard , J-P , Coelho , L P , Galleron , N , Hansen , T H , Hulot , J-S , Lewinter , C , Pedersen , H K , Quinquis , B , Rouault , C , Roume , H , Salem , J-E , Søndertoft , N B , Touch , S , Dumas , M-E , Ehrlich , S D , Galan , P , Gøtze , J P , Hansen , T , Holst , J J , Køber , L , Letunic , I , Nielsen , J , Oppert , J-M , Stumvoll , M , Vestergaard , H , Zucker , J-D , Bork , P , Pedersen , O , Bäckhed , F , Clément , K , Raes , J & MetaCardis Consortium 2020 , ' Statin therapy is associated with lower prevalence of gut microbiota dysbiosis ' , Nature , vol. 581 , no. 7808 , pp. 310-315 .
Publication Year :
2020

Abstract

Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible

Details

Database :
OAIster
Journal :
Vieira-Silva , S , Falony , G , Belda , E , Nielsen , T , Aron-Wisnewsky , J , Chakaroun , R , Forslund , S K , Assmann , K , Valles-Colomer , M , Nguyen , T T D , Proost , S , Prifti , E , Tremaroli , V , Pons , N , Le Chatelier , E , Andreelli , F , Bastard , J-P , Coelho , L P , Galleron , N , Hansen , T H , Hulot , J-S , Lewinter , C , Pedersen , H K , Quinquis , B , Rouault , C , Roume , H , Salem , J-E , Søndertoft , N B , Touch , S , Dumas , M-E , Ehrlich , S D , Galan , P , Gøtze , J P , Hansen , T , Holst , J J , Køber , L , Letunic , I , Nielsen , J , Oppert , J-M , Stumvoll , M , Vestergaard , H , Zucker , J-D , Bork , P , Pedersen , O , Bäckhed , F , Clément , K , Raes , J & MetaCardis Consortium 2020 , ' Statin therapy is associated with lower prevalence of gut microbiota dysbiosis ' , Nature , vol. 581 , no. 7808 , pp. 310-315 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1322754334
Document Type :
Electronic Resource